Peptoid Compound Detection Chip for CTC Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liquid biopsy technologies face challenges in detecting circulating tumor cells (CTC) due to their low concentration and similar size to white blood cells, and the random arrangement of antibody molecules on biosensors leads to low specificity and high costs.
Innovation Solution
Development of peptoid compounds with specific subunits, such as 1,4-butanediamine, 2-(4-biphenylyl)ethylamine, and 3-aminopropionic acid, which form macromolecules that can be synthesized to create ordered arrangements on sensors, providing high affinity and stability for EpCAM protein detection, and are used on a detection chip for CTC identification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Force
If antibody molecules are used as probe molecules for CTC detection, then binding affinity to EpCAM protein is improved, but the arrangement on sensor surface becomes random and specificity decreases
Solution Approach 1:
The patent changes the chemical structure parameters of the probe molecule from natural antibodies to synthesized peptoid compounds with specific amino acid sequences. This structural parameter change enables controlled orientation and arrangement on the sensor surface while maintaining high binding affinity to EpCAM protein, resolving the contradiction between binding strength and arrangement control.
2Measurement precision
If antibody molecules are used for CTC detection, then detection capability is improved, but manufacturing cost increases
Solution Approach 1:
The patent replaces expensive antibodies with cost-effective peptoid compounds that can be synthesized through chemical methods. These peptoid probes maintain high detection capability for CTCs while significantly reducing manufacturing costs, making the detection system more economically viable for clinical applications.
3Measurement precision
If tissue biopsy is performed to detect tumor cells, then comprehensive tumor condition assessment is improved, but sampling completeness deteriorates due to tumor heterogeneity
Solution Approach 1:
The patent extracts and detects circulating tumor cells from blood samples instead of requiring comprehensive tissue sampling. This extraction approach allows detection of tumor cells distributed throughout the bloodstream, providing a more complete picture of tumor burden and heterogeneity without the limitations of single-site tissue biopsy.
4Ease of operation
If liquid biopsy is used to detect CTCs, then non-invasive detection is improved, but detection sensitivity deteriorates due to low CTC concentration and similar size to white blood cells
Solution Approach 1:
The patent applies local quality by functionalizing the sensor surface with specific peptoid probes that have high affinity for EpCAM protein on CTC surfaces. This localized molecular recognition capability enables the sensor to distinguish CTCs from white blood cells based on surface protein expression, significantly improving detection sensitivity while maintaining the non-invasive liquid biopsy approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptoid compounds demonstrate strong binding to EpCAM proteins, enabling sensitive detection of CTCs with high specificity and low manufacturing costs, effectively distinguishing cancer patients from healthy individuals, and reducing non-specific adsorption on the chip surface.
Implementation Method 1
specific capture is achieved through the affinity of the probe molecules and CTC surface proteins
Data Source
AI summary
Embodiments disclosed herein provide a peptoid compound comprising a structure shown in Formula I and a detection chip having the peptoid compound coupled onto its surface. The peptoid compound has a strong binding ability with EpCAM protein on the surface of circulating tumor cells. The diagnostic technology of colorectal adenocarcinoma, gastric adenocarcinoma, breast cancer, ovarian cancer, lung adenocarcinoma, prostate cancer, pancreatic cancer, stem cell cancer, retinoblastoma, or primary esophageal squamous cell carcinoma based on the peptoid compound can realize rapid detection or diagnosis. In addition, the peptoid compound can be made by a simple synthesis method with high preparation efficiency and low production cost.